Format

Send to

Choose Destination
Bioorg Med Chem. 2015 Jul 1;23(13):3081-90. doi: 10.1016/j.bmc.2015.05.003. Epub 2015 May 11.

Selective inhibition of prolyl 4-hydroxylases by bipyridinedicarboxylates.

Author information

1
Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, United States.
2
Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, United States; Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, United States. Electronic address: rtraines@wisc.edu.

Abstract

Collagen is the most abundant protein in animals. A variety of indications are associated with the overproduction of collagen, including fibrotic diseases and cancer metastasis. The stability of collagen relies on the posttranslational modification of proline residues to form (2S,4R)-4-hydroxyproline. This modification is catalyzed by collagen prolyl 4-hydroxylases (CP4Hs), which are Fe(II)- and α-ketoglutarate (AKG)-dependent dioxygenases located in the lumen of the endoplasmic reticulum. Human CP4Hs are validated targets for treatment of both fibrotic diseases and metastatic breast cancer. Herein, we report on 2,2'-bipyridinedicarboxylates as inhibitors of a human CP4H. Although most 2,2'-bipyridinedicarboxylates are capable of inhibition via iron sequestration, the 4,5'- and 5,5'-dicarboxylates were found to be potent competitive inhibitors of CP4H, and the 5,5'-dicarboxylate was selective in its inhibitory activity. Our findings clarify a strategy for developing CP4H inhibitors of clinical utility.

KEYWORDS:

Collagen; Hydroxyproline; Hypoxia-inducible factor; Iron; α-Ketoglutarate

PMID:
26022078
PMCID:
PMC4552733
DOI:
10.1016/j.bmc.2015.05.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center